People In Brief
This article was originally published in The Tan Sheet
Executive Summary
Waxman staffer rejoins FDA: Ann Witt, health counsel to Rep. Henry Waxman, heads back to FDA, marking the second former staffer for the California Democrat to hold a prominent position in the agency under the Obama administration. Witt is expected to take a post in the Office of Policy, Planning and Budget this time around. She previously served as acting director of the drug center's Division of Drug Marketing, Advertising & Communications, and as an advisor in the Office of the Commissioner. Josh Sharfstein, FDA's principal deputy commissioner, previously was Waxman's health policy advisor (1"The Tan Sheet" April 13, 2009)
You may also be interested in...
Litigation In Brief
Antioxidant claims basis for FDA suit: In his third lawsuit filed against FDA in less than a month, attorney Jonathan Emord alleges FDA "created a rigid construct that categorically rejects a large quantum of peer-reviewed science," namely qualified health claims linking antioxidant vitamins C and E with reduced risk of site-specific cancers. Emord's 1complaint, filed Aug. 14 in the U.S. District Court for the District of Columbia, says FDA violated First Amendment-based precedent in denying the claims for which he petitioned in 2008. As with the similar recent suit Emord filed against FDA for rejecting selenium QHCs, the Clifton, Va.-based attorney represents the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship, and businesspeople Durk Pearson and Sandy Shaw (2"The Tan Sheet" Aug. 3, 2009, In Brief)
Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC